-sartan
An angiotensin II receptor blocker (ARB): stops angiotensin II acting on blood vessels, lowering blood pressure.
- Drugs ending in -sartan: 15
- Approved somewhere: 8
- With a US drug page: 7
- Stem
- -sartan
- Class
- Angiotensin II receptor blockers, which lower blood pressure
Approved and clinical-stage drugs in ChEMBL whose names ending in -sartan, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Candesartan cilexetil | Approved | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Eprosartan | Approved | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Irbesartan | Approved | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Losartan | Approved | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Olmesartan medoxomil | Approved | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Telmisartan | Approved | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Valsartan | Approved | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Azilsartan medoxomil | Approved | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Azilsartan | Phase 3 | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Candesartan | Phase 3 | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Fimasartan | Phase 3 | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Olmesartan | Phase 3 | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Tasosartan | Phase 2 | AGTR1 | Type-1 angiotensin II receptor antagonist |
| Fimasartan potassium trihydrate | Phase 1 | โ | โ |
| Pratosartan | โ | AGTR1, SLC22A12, SLC22A6, SLC22A8 | Type-1 angiotensin II receptor antagonist |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO